The escalating trade war between the US and Canada could be a disaster...
- Are US pharma companies immune to US–Canada trade wars?
- Deals and M&As this week: Alliance Pharma, Bayer, Onxeo
- Merck to distribute HistoCyte Laboratories’ cell line products
- Researchers identify brain metals that may precipitate Alzheimer’s
- Regenerative therapy for peripheral artery disease moves forward
Are US pharma companies immune to US–Canada trade wars?
The escalating trade war between the US and Canada could be a disaster for US pharma companies as they face the threat of expropriation of intellectual property from the Canadian government.
T2620 Inline Serialization – A Fully Integrated Compact System
T2620 Inline Serialization system enables carton serialisation to meet product traceability and compliance requirements as per regulation such as the Falsified Medicines Directive in Europe and the Drug Supply Chain Security Act in the US.
Security of Pharmaceuticals – Comparing US and EU Standards
What do the Falsified Medicine Directive (FMD) and the Drug Supply Chain Security Act (DSCSA) in common and what are their differences? This white paper presents the main provisions of both legal frameworks and assists in developing a deeper understanding of the requirements for pharmaceutical companies.
Deals and M&As this week: Alliance Pharma, Bayer, Onxeo
Alliance Pharma plans to acquire exclusive distribution rights to Nizoral, an anti-dandruff brand, from Janssen Pharmaceutica NV for £60m ($79.5m).
Merck to distribute HistoCyte Laboratories’ cell line products
Pharmaceutical company Merck has signed an agreement to become the exclusive multinational distributor of HistoCyte Laboratories’ portfolio of cell line reference products for immunohistochemistry and in situ hybridisation.
Researchers identify brain metals that may precipitate Alzheimer’s
A research team including members from Warwick’s School of Engineering has identified and characterised certain brain metals that may precipitate the progression of Alzheimer’s disease.
Regenerative therapy for peripheral artery disease moves forward
Encouraging Phase II results were released last week for Pluristem’s PLX-PAD, a placenta-based allogeneic stem cell therapy given intramuscularly, targeting peripheral artery disease (PAD). The positive results are great news for patients who suffer from PAD, a circulatory problem in which narrowed arteries reduce blood flow to the limbs, which has limited treatment options available.
Aspen Pharma’s High-Containment Manufacturing Facility, Port Elizabeth, South Africa
In May 2018, pharmaceutical manufacturing firm Aspen Pharma opened a new high-containment facility in Port Elizabeth, South Africa.
Natera and Institut Jules Bordet partner on breast cancer research
Genetic testing company Natera has partnered with the Belgian Institut Jules Bordet to advance breast cancer research.
Study finds drug reduces hearing loss in children with liver cancer
A study has found that a new drug sodium thiosulphate (STS) can reduce hearing loss in children treated for hepatoblastoma, a childhood liver cancer.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.